Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Closes Third Round of Financing; In Talks With FDA for US Launch

NEW YORK, June 2 (GenomeWeb News) - Dutch biotech Agendia has closed a third round of financing with the Van Herk Group and Gilde Healthcare, the company said today. It did not disclose the amount of the financing.


The cash will help Agendia develop its microarray-based late stage products into diagnostics for breast cancer and other cancer types. It will also help the company to globally market its CupPrint and MammaPrint prognostic breast cancer tests.


Agendia CEO Bernhard Sixt said the company is expanding its EU presence and is in "advanced" talks with the FDA to enter the US market.


Van Herk Group, Gilde Healthcare, AXA Private Equity Venture Funds, Global Life Sciences Ventures, and the Netherlands Cancer Institute are current investors.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.